Wall Street Zen Upgrades Bausch + Lomb (NYSE:BLCO) to Strong-Buy

Key Points

• Wall Street Zen upgraded Bausch + Lomb to “strong buy” from “buy,” while other analysts remained mixed; MarketBeat’s overall consensus is “hold” with an average price target of $20.75.
• Bausch + Lomb reported quarterly earnings of $0.34 per share, beating the $0.21 consensus, with revenue of $1.38 billion—up 7.3% year over year and slightly above expectations.
• The stock opened at $19.99, near its 52-week high of $21.36, while insiders have sold approximately $1.19 million worth of shares over the past 90 days.

Bausch + Lomb (NYSE:BLCO - Get Free Report) was upgraded by Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued on Saturday, Wall Street Zen reports.

Several other equities research analysts have also recently weighed in on BLCO. Barclays raised shares of Bausch + Lomb to a "strong-buy" rating in a research report on Wednesday, October 7th. HC Wainwright restated a "buy" rating and issued a $21.00 target price on shares of Bausch + Lomb in a research report on Friday, August 28th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $20.00 target price on shares of Bausch + Lomb in a research report on Thursday. Needham & Company LLC reaffirmed a "hold" rating on shares of Bausch + Lomb in a report on Tuesday, September 15th. Finally, Leerink Partners assumed coverage on shares of Bausch + Lomb in a research report on Wednesday, September 9th. They set an "outperform" rating and a $24.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $20.75.

Bausch + Lomb Stock Performance

NYSE:BLCO opened at $19.99 on Friday. The stock has a fifty day moving average price of $17.35 and a 200-day moving average price of $16.69. The company has a market cap of $7.14 billion, a price-to-earnings ratio of -64.48, a PEG ratio of 0.60 and a beta of 0.56. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.02 and a current ratio of 1.56. Bausch + Lomb has a fifty-two week low of $14.44 and a fifty-two week high of $21.36.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The company reported $0.34 EPS for the quarter, topping analysts' consensus estimates of $0.21 by $0.13. Bausch + Lomb had a positive return on equity of 5.01% and a negative net margin of 2.05%. The company had revenue of $1.38 billion for the quarter, compared to analysts' expectations of $1.37 billion. During the same quarter last year, the business earned $0.18 earnings per share. Bausch + Lomb's revenue was up 7.3% on a year-over-year basis. As a group, equities analysts anticipate that Bausch + Lomb will post 0.86 EPS for the current fiscal year.

Insider Activity

In related news, CAO Frederick Munsch sold 52,900 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $16.78, for a total value of $887,662.00. Following the completion of the transaction, the chief accounting officer owned 45,831 shares in the company, valued at $769,044.18. This trade represents a 53.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Eschenbach Andrew C. Von sold 6,059 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $16.58, for a total transaction of $100,458.22. Following the completion of the transaction, the director owned 63,733 shares of the company's stock, valued at approximately $1,056,693.14. This trade represents a 8.68% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 71,459 shares of company stock worth $1,194,370. Company insiders own 1.45% of the company's stock.

Hedge Funds Weigh In On Bausch + Lomb

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Beach Point Capital Management LP bought a new stake in shares of Bausch + Lomb in the third quarter worth $5,882,000. Whitebox Advisors LLC raised its position in Bausch + Lomb by 15.8% during the 1st quarter. Whitebox Advisors LLC now owns 1,101,854 shares of the company's stock worth $17,519,000 after purchasing an additional 150,641 shares during the last quarter. Engineers Gate Manager LP acquired a new position in Bausch + Lomb during the 2nd quarter worth about $1,479,000. Sei Investments Co. lifted its holdings in Bausch + Lomb by 100.0% during the 1st quarter. Sei Investments Co. now owns 139,266 shares of the company's stock worth $2,214,000 after buying an additional 69,633 shares during the period. Finally, Counterpoint Mutual Funds LLC bought a new stake in shares of Bausch + Lomb in the 3rd quarter valued at about $670,000. 11.07% of the stock is currently owned by institutional investors and hedge funds.

More Bausch + Lomb News

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Strong quarterly results: Bausch + Lomb reported adjusted earnings of $0.34 per share, well above the $0.21 consensus estimate, while revenue reached approximately $1.38 billion versus expectations of $1.37 billion. Revenue increased 7.3% year over year. Bausch + Lomb Q3 2026 Earnings
• Positive Sentiment: Higher 2026 guidance: Management raised its forecast to $5.450 billion-$5.550 billion in revenue and $1.090 billion-$1.140 billion in adjusted EBITDA, citing continued momentum from its Vision ’27 strategy. The improved outlook supports investor confidence in growth and profitability. Bausch + Lomb Raises 2026 Guidance
• Positive Sentiment: Analysts raised targets: RBC lifted its price target from $21 to $23 and maintained an “outperform” rating. JPMorgan raised its target from $16 to $22, although it retained a “neutral” rating. The revisions indicate that analysts see improved earnings potential following the results. RBC Raises BLCO Price Target
• Neutral Sentiment: Deutsche Bank raised its target from $16 to $20 but kept a “hold” rating, while Wells Fargo increased its target from $18 to $19 and maintained an “equal weight” rating. These calls reflect more cautious views after the stock’s recent advance. Deutsche Bank Adjusts BLCO Price Target

Bausch + Lomb Company Profile

Bausch + Lomb Corporation NYSE: BLCO is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.